{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015702","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.556520+00:00","generated_at":"2026-05-30T00:40:01.448955+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adagio Medical Q3 2024 revenue $185K (+351% YoY); net loss $4.6M; CMS coverage secured","bullets":["Revenue of $185K in Q3 2024, up 351% from $41K in Q3 2023.","Net loss of $4.6M improved from $10.8M in Q3 2023; driven by fair value changes on convertible notes.","Cash and short-term investments of $28.3M as of September 30, 2024.","CMS Category B coverage secured for vCLAS catheter in FULCRUM-VT IDE study for drug-resistant VT.","First procedures performed in FULCRUM-VT pivotal study; 206 patients at 20 US/Canadian centers to support FDA PMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015702","json":"https://secwatch.observer/filing/0001558370-24-015702.json","markdown":"https://secwatch.observer/filing/0001558370-24-015702.md","text":"https://secwatch.observer/filing/0001558370-24-015702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000155837024015702/0001558370-24-015702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000155837024015702/adgm-20241114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:40:01.448955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}